The Trump administration's TrumpRx program, launched in early February 2026 as part of a broader push to align U.S. prescription drug prices with the lowest rates paid in other developed nations, continues to expand its list of discounted medications. As of mid-March, the government-run website trumprx.gov features more than 50 brand-name drugs available at steep cash-pay discounts, often touted as "the world's lowest prices."

TrumpRx Launches: President Trump Unveils Discounted Drugs Website
TrumpRx Launches: President Trump Unveils Discounted Drugs Website

The initiative, rooted in President Donald Trump's May 2025 executive order on Most-Favored-Nation (MFN) pricing, allows uninsured patients or those paying out-of-pocket to access coupons or direct purchases for select medications at reduced rates. Recent additions from companies like Amgen and GSK have brought the total to around 54 drugs, covering conditions from obesity and diabetes to respiratory issues, fertility treatments, autoimmune disorders and more.

TrumpRx sorts medications by "Best Deal (% Off)," highlighting the largest percentage reductions from list prices. Among the top 10 cheapest options based on current TrumpRx pricing — typically for standard supplies or monthly doses — are several standout bargains:

1. **Cetrotide** — Starting at $22.50 (from $316.12, 93% off). This fertility drug, used in IVF regimens, tops many lists as the lowest-priced item on the platform.

2. **Mayzent** — Starting at $42.00 (from $623.00, 93% off). A treatment for multiple sclerosis, it ranks high for percentage savings.

3. **Bevespi** — $51.00 (from $458.05, 89% off). An inhaler for chronic obstructive pulmonary disease (COPD) and respiratory conditions.

4. **Duavee** — $30.30 (from $202.00, 85% off). Used for menopausal symptom relief.

5. **Toviaz** — Starting at $43.50 (from $290.00, 85% off). For overactive bladder treatment.

6. **Wegovy Pill** — Starting at $149.00 (from $1,349.02, 89% off). The oral form of the popular GLP-1 weight-loss and diabetes medication.

7. **Wegovy Pen** — Starting at $199.00 (from $1,349.02, up to 85% off). The injectable version, with pricing varying by dosage.

8. **Ozempic Pen** — $199.00 (from $1,027.51, 81% off). Another semaglutide-based drug for type 2 diabetes and weight management.

9. **Zepbound** — $299.00 (from $1,087, around 72% off). Eli Lilly's tirzepatide for obesity and diabetes.

10. **Airsupra** — Around $201 (respiratory rescue inhaler, significant discount from list).

These prices reflect cash-pay or self-pay scenarios, often via printable coupons redeemable at participating pharmacies. The White House emphasizes that discounts stem from negotiated MFN deals with manufacturers including Novo Nordisk, Pfizer, AstraZeneca, Eli Lilly, EMD Serono, Amgen and GSK. For high-cost GLP-1 drugs like Wegovy and Ozempic, monthly supplies drop dramatically, making them accessible for uninsured patients facing list prices exceeding $1,000.

Administration officials highlight the program's role in curbing "Big Pharma price-gouging," with expansions adding treatments like Amgen's Amjevita (rheumatoid arthritis biosimilar at $299 from $1,484) and GSK's Incruse (COPD at $159). The site now includes more respiratory and autoimmune options, broadening appeal.

Critics and analysts note limitations. Many listed drugs — roughly half at launch — have cheaper generic equivalents available through platforms like GoodRx or Mark Cuban's Cost Plus Drugs. For instance, some antidepressants or acid-reflux treatments on TrumpRx cost more than their generics elsewhere. Experts from KFF and STAT News point out that TrumpRx targets brand-name medications, and savings may not beat alternatives for patients with access to generics.

The program excludes certain states like California and Massachusetts due to laws restricting manufacturer coupons when generics exist. It requires a valid prescription, and not all pharmacies honor the discounts uniformly. Patients are advised to compare with insurance coverage first, as TrumpRx focuses on uninsured or high-deductible scenarios.

Public reception varies. KFF polling shows partisan divides, with Republicans more optimistic about cost reductions, while broader support exists for greater government regulation of drug prices. About one-third of prescription medication users have heard of TrumpRx, with higher awareness among those on GLP-1 drugs.

As more manufacturers join under tariff reprieve incentives, the administration promises further additions. TrumpRx remains a direct-to-consumer tool rather than a full replacement for insurance or traditional pharmacies, but its deep cuts on select high-profile drugs — especially fertility and weight-loss options — provide tangible relief for cash-paying Americans.

With ongoing negotiations and potential congressional codification in Trump's "Great Healthcare Plan," the program represents one piece of a multifaceted approach to affordability. Patients can browse trumprx.gov for the latest list, compare prices and generate coupons, though experts urge verifying options against generics for maximum savings.